



# Overview of New Donor Heart Allocation Tiers

Dan M. Meyer, MD  
University of Texas Southwestern  
Dallas, Texas

---



CUTTING EDGE OF  
TRANSPLANTATION

AST | AMERICAN SOCIETY OF  
TRANSPLANTATION

**RESOLVING THE ORGAN SHORTAGE**



PRACTICE |



POLICY |



POLITICS

FEBRUARY 25-27, 2016 • PHOENIX, ARIZONA

# Conflict of Interest Disclosure

I have no relevant financial relationships to disclose.

# Background

The Heart Subcommittee was asked by the UNOS Board to explore opportunities for broader, more equitable sharing of donor hearts.

Review requested because of

- 1) the increase of candidates waiting without a corresponding increase in available donors
- 2) higher than desirable waiting list mortality rates in higher status patients and
- 3) changing management of heart failure patients with the increased use of VADs.

# Goals

- Reduce waiting list mortality rates
- Reduce the use of exceptions by better accommodating all candidates within the system
- Ensure that qualifying criteria for the statuses are based on objective physiological indications rather than therapeutic intervention
- Improve overall access to transplantation by modifying geographic distribution to ensure maximum utilization of donor hearts

# Options Considered

Modify current 3-tiered system

Develop heart allocation score

Add more tiers

# How was the proposal developed?

Identify patients with high waitlist mortality

- Considerations: waitlist mortality, transplant rates and post-transplant survival


Define “criteria” for subjective decisions based upon objective data elements and physiological principles

Explore options for broader sharing for the sickest patients

Integrate pediatric allocation


Model the above and hope/pray that the data is interpretable, accurate and explainable

# % died within 6 months: medical urgency status at listing/transplant



UNOS Data, 2013

# % died within 6 months\*: ever waiting in criteria



\* For WL analysis, time is computed from first entry into criteria, rather than time since listing.


**Criteria:**

- A = Mechanical circulatory support (i.e., VAD for 30 days, TAH, balloon pump, ECMO)
- B = Mechanical circulatory support with device complications
- C = Mechanical ventilation
- D = Continuous infusion of single high dose or multiple inotropes + continuous hemodynamic monitoring
- E = Exception

UNOS Data, 2013



# % died within 6 months\*: ever waiting in criteria or sub-criteria



\* For WL analysis, time is computed from first entry into criteria/sub-criteria, rather than time since listing.


**Sub-criteria:**

- A(i) = VAD for 30 days
- A(ii) = TAH
- A(iii) = Intra-aortic balloon pump
- A(iv) = ECMO

- B(i) = Thromboembolism
- B(ii) = Device infection
- B(iii) = Device malfunction
- B(iv) = Life-threatening ventricular arrhythmia
- B(v) = Other device related complication

UNOS Data, 2013

# Categories for adult status 1A exception



IA - Urgent	IA	IB - U	IB	ACO	2	7
Status IA (a) Subcriteria IV - ECMO	Status IA (a) Subcriteria III IABP	Status IA (a) Subcriteria I (VAD for 30d)	Retransplantation			
Status IA (c) mechanical ventilation	Amyloid	Status IA (e)	CHD		Sensitized patient	
Status IA (a) (Circulatory support device)	Status IA (b) (device complication)	Status IA (d) (IV Inotropes & continuous hemodynamic monitoring)	Ischemic CMP		Zonal Sharing	
VT/VF	Status IA (a) Subcriteria II TAH	Status IA (b) Subcriteria V Other device related complications	HOCM Hypertrophic CMP		VAD Complexn	
	Status IA (b) Subcriteria IV Life threatening Vent. arrhythmias	Status IA (b) Subcriteria II Device Infection	Restrictive CMP		Unable to place lines	
	Status IA (b) Subcriteria III Device malfunction					

## Table of waiting list and post-transplant outcomes by tier and criteria (1)

Tier and subtier		Waitlist outcomes						Post-tx outcome		
		Obs Days	Tx	Tx rate	Deaths	Death rate	Death/ too sick	Death/ too sick rate	Deaths	Death rate
<b>Tier 1</b>	1a ECMO	432	13	1099.1	18	1521.9	21	1775.5	5	26.7
	1b Mech Vent	1086	15	504.5	6	201.8	9	302.7	5	24.7
	1ci Non-disch R/BiVAD	404	15	1356.1	2	180.8	3	271.2	3	10.9
	1ci VAD+Vent Arrhy	1714	21	447.5	2	42.6	2	42.6	4	11.1
<b>Tier 2</b>	2a IABP	5263	168	1165.9	15	104.1	18	124.9	26	8.7
	2b VT/VT	11392	88	282.1	4	12.8	6	19.2	12	7.7
	2c Dev Malfn/failure	6996	71	370.7	6	31.3	7	36.5	8	6.2
	2d TAH	4015	48	436.7	0	0.0	0	0.0	10	12.6
	2e Disch R/BiVAD	2076	43	756.5	0	0.0	0	0.0	5	6.2
<b>Tier 3</b>	3a LVAD for 30d	31563	513	593.6	15	17.4	15	17.4	65	7.0
	3b Stat 1A Exception	6863	138	734.4	7	37.3	10	53.2	24	10.0
	3c Inotropes w/Monitor	28603	700	893.9	15	19.2	24	30.6	77	5.9
	3d Oth Dev Comp	5769	74	468.5	2	12.7	2	12.7	12	9.1
	3e Dev Infection	31108	261	306.4	6	7.0	9	10.6	53	11.9
	3f Thromboembolism	5253	85	591.0	2	13.9	2	13.9	11	7.1

SRTR Data, 2/2014

# Proposed Statuses 1-3

Status	Criteria
1	<ul style="list-style-type: none"> <li>• ECMO</li> <li>• Continuous Mechanical ventilation</li> <li>• Non-dischargeable (surgically implanted) VAD</li> <li>• MCSD with life-threatening ventricular arrhythmia</li> </ul>
2	<ul style="list-style-type: none"> <li>• Intra-aortic balloon pump</li> <li>• Ventricular tachycardia/ventricular fibrillation, mechanical support not required</li> <li>• MCSD with device malfunction/mechanical failure</li> <li>• Total artificial heart</li> <li>• Dischargeable BiVAD or RVAD</li> <li>• Acute circulatory support</li> </ul>
3	<ul style="list-style-type: none"> <li>• Dischargeable LVAD for up to 30 days</li> <li>• Multiple inotropes or single high-dose inotropes with continuous hemodynamic monitoring</li> <li>• MCSD with device infection</li> <li>• MCSD with hemolysis</li> <li>• MCSD with pump thrombosis</li> <li>• MCSD with right heart failure</li> <li>• MCSD with mucosal bleeding</li> <li>• MCSD with aortic insufficiency</li> </ul>

# Proposed Statuses 4-6

Status	Criteria
4	<ul style="list-style-type: none"><li>• Stable LVAD candidates not using 30 day discretionary period</li><li>• Inotropes without hemodynamic monitoring</li><li>• Diagnosis of congenital heart disease (CHD)</li><li>• Diagnosis of ischemic heart disease with intractable angina</li><li>• Diagnosis of hypertrophic cardiomyopathy</li><li>• Diagnosis of restrictive cardiomyopathy</li><li>• Diagnosis of amyloidosis</li><li>• Retransplant</li></ul>
5	Combined organ transplants
6	All remaining active candidates

# Geographic Sharing Background

## Problem

- DSA boundaries create inequities in access to transplant, particularly for the most urgent candidates


## Goal

- Increase the number of donors available to the most critically ill patients, without increasing the number of discarded organs

## Status

- TSAM request submitted for 4 different allocations sequences

# Where Would You Want to Be Waiting As Status I?




% of pts listed as Status I  
who have been waiting > 6 Months


*UNOS Data as of April 12, 2013*




# Broader Sharing For Tier 1



**Offer 1 (All tier 1s in DSA + Zone A + Zone B)**



**Offer 2 (All Tier 2s in DSA + Zone A)**




**Offer 3 (All Tier 3s in DSA + Zone A)**

# Two Preferred Modeled Sequences

Broader sharing 1/2A		Broader sharing 1/2B	
Candidate status	Location	Candidate status	Location
Status 1 adult + Status 1A ped	DSA + Zone A	Status 1 adult + Status 1A ped	DSA + Zone A
Status 1 adult + Status 1A ped	Zone B	Status 1 adult + Status 1A ped	Zone B
Status 2 adult	DSA + Zone A	Status 2 adult	DSA + Zone A
Status 2 adult	Zone B	Status 2 adult	Zone B
Status 3 adult + Status 1B ped	DSA	Status 3 adult + Status 1B ped	DSA
Status 4 adult	DSA	Status 3 adult + Status 1B ped	Zone A
Status 3 adult + Status 1B ped	Zone A	Status 4 adult	DSA


SRTR Data, 2/2014

# Overall waitlist mortality rates by simulation



SRTR Data, 2/2014

# Two-year post-transplant mortality rates by simulation




SRTR Data, 2/2014

# Conclusions


- Multi-tiered system serves to address the problems noted in the current system
  - Reduce waiting list mortality rates – allocate organs to the most critically ill candidates
  - Addresses issues with specific patients groups, some possibly disenfranchised in today's allocation system
  - Incorporates broader geographic sharing to optimize access and limit regional disparities that may exist
- Post-transplant survival - within each status, projected to remain comparable to those rates in the current system



# Waitlist mortality rates by simulation



# Transplant rates by simulation







# Multi-Organ Transplantation

Heart-Lung

Heart + Abdominal Organ(s)




Am J Transplant 2009;9:844-52

# Problems with the Current System

1. Status 1A candidates are 3x more likely to die on the waiting list than candidates in any other status
2. High # of exception requests indicates certain candidates not served well by current system
3. Policy out of date re: increased use of MCSDs and associated complications
4. Current geographic sharing scheme is inequitable and inconsistent with the Final Rule

# Who gets the first offer?



# Proposed New Statuses

Current Status	Proposed Status
1A	1
	2
	3
1B	4
2	5
	6

- Proposed statuses 1-3 are generally defined by current status 1A criteria
- Proposed status 4 is generally defined by current status 1B criteria
- Proposed status 5-6 are generally defined by current status 2 criteria